Brian Zehr, MD
Pulmonary Disease · Fort Wayne, INNPI 1619911005
Payments from drug & device makers
Across 98 payments — averaging $25.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$422
- Regeneron Healthcare Solutions, Inc.$394
- Takeda Pharmaceuticals U.S.A., Inc.$212
- Actelion Pharmaceuticals US, Inc.$162
- Boehringer Ingelheim$158
- Mallinckrodt Hospital Products Inc.$158
- plus $980 from 17 others
What the payments were for
- Food & beverage$2,27291%
- Education$2159%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $422 |
| Regeneron Healthcare Solutions, Inc. | 11 | $394 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $212 |
| Actelion Pharmaceuticals US, Inc. | 3 | $162 |
| Boehringer Ingelheim | 4 | $158 |
| Mallinckrodt Hospital Products Inc. | 5 | $158 |
| Sanofi | 4 | $139 |
| GSK | 8 | $123 |
| Genentech USA, Inc. | 5 | $117 |
| Inogen, Inc. | 6 | $104 |
| Grifols USA, LLC | 4 | $84 |
| Amgen | 4 | $80 |
| United Therapeutics Corporation | 3 | $57 |
| Pulmonx Corporation | 3 | $57 |
| Mylan Specialty L.p. | 3 | $44 |
| Insmed, Inc. | 2 | $34 |
| Philips North America LLC | 2 | $33 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Electromed, Inc. | 2 | $20 |
| CSL Behring | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $15 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,487 in reported general payments places this provider in the 50th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 661 | $564,868 |
| OfevNintedanib Esylate | 18 | $237,223 |
| Breo ElliptaFluticasone/Vilanterol | 252 | $132,100 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $54,815 |
| Dupixent PenDupilumab | 13 | $47,579 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 66 | $42,723 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $31,831 |
| Arnuity ElliptaFluticasone Furoate | 98 | $31,027 |
| Pirfenidone | 40 | $23,074 |
| Spiriva HandihalerTiotropium Bromide | 25 | $22,540 |
| SymbicortBudesonide/Formoterol Fumarate | 63 | $19,022 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 113 | $16,113 |
| Spiriva RespimatTiotropium Bromide | 14 | $8,546 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $8,052 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 219 | $7,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $123 | $778,7701,093 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $158 | $277,60069 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $422 | $73,837123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Fort Wayne
- Daria LeeFort Wayne$80K
- Vicente RodriguezFort Wayne$43K
- Abhishek BiswasFort Wayne$30K
- Bharat BajantriFort Wayne$29K
- Vatche IsrabianFort Wayne$22K
- Shivu KaushikFort Wayne$10K
- Cynthia BrownIndianapolis$7.3M
- Imad ShawaGreenwood$1.4M
- David MaresAnderson$1.3M
- Raja DevanathanHobart$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.